Electroporation of immature and mature dendritic cells: Implications for dendritic cell-based vaccines

Gene Therapy

Volumn 12, Issue 9, 2005, Pages 772-782

  Michiels, A ^a   Tuyaerts, S ^a   Bonehill, A ^a   Corthals, J ^a   Breckpot, K ^a   Heirman, C ^a   Van Meirvenne, S ^a   Dullaers, M ^a   Allard, S ^a   Brasseur, F ^b   van der Bruggen, P ^b   Thielemans, K ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Antigen presentation; Cancer immunotherapy; Dendritic cells; mRNA electroporation

Indexed keywords

CD40 ANTIGEN; CHEMOKINE; CYTOKINE; DENDRITIC CELL VACCINE;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL BASED GENE THERAPY; CELL MATURATION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE RELEASE; DENDRITIC CELL; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VACCINATION;

ANTIGEN PRESENTATION; CANCER VACCINES; CELL DIFFERENTIATION; CELL SURVIVAL; CRYOPRESERVATION; CYTOKINES; DENDRITIC CELLS; ELECTROPORATION; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFECTION;

EID: 20844459312     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302471     Document Type: Article

References (56)

1. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-594.
2. Hung K et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368.
3. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
4. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
6. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol 1999; 72: 255-324.
7. Banchereau J et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
8. Guermonprez P et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-667.
9. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-273.
10. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 94: 459-473.
11. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 2001; 29: 1247-1255.
12. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106: 271-274.
13. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11: 263-270.
14. Tuyaerts S et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002; 264: 135-151.
15. Romani N et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93.
16. Jonuleit H et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135-3142.
17. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000; 11: 797-806.
18. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 2002; 25: 289-303.
19. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000; 106: 1065-1069.
20. Ponsaerts P, Van Tendeloo VF, Berneman ZN. Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 2003; 134: 378-384.
21. Thurner B et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-1678.
22. Santin AD et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999; 73: 5402-5410.
23. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998; 5: 231-252.
24. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997; 185: 909-920.
25. Tobery T, Siliciano RF. Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol 1999; 162: 639-642.
26. Varshavsky A. Recent studies of the ubiquitin system and the N-end rule pathway. Harvey Lect 2000; 96: 93-116.
27. Bonini C, Lee SP, Riddell SR, Greenberg PD. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 2001; 166: 5250-5257.
28. Lin KY et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
29. Thomson SA et al. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol 1998; 72: 2246-2252.
30. Su Z et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002; 62: 5041-5048.
31. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46: 82-87.
32. Nair SK et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16: 364-369.
33. Heiser A et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164: 5508-5514.
34. Heiser A et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109: 409-417.
35. Heiser A et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001; 61: 3388-3393.
36. Thornburg C, Boczkowski D, Gilboa E, Nair SK. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. J Immunother 2000; 23: 412-418.
37. Van Tendeloo VF et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98: 49-56.
38. Saeboe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002; 259: 191-203.
39. Kalady MF et al. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J Surg Res 2002; 105: 17-24.
40. Tuyaerts S et al. Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther 2003; 10: 696-706.
41. Bonehill A et al. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res 2003; 63: 5587-5594.
42. Milazzo C et al. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003; 101: 977-982.
43. Larsson M et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol 2000; 165: 1182-1190.
44. Lewalle P, Rouas R, Lehmann F, Martiat P. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli. J Immunol Methods 2000; 240: 69-78.
45. Feuerstein B et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000; 245: 15-29.
46. Romani N et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137-151.
47. Lee AW et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002; 20 (Suppl 4): A8-A22.
48. Scandella E et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002; 100: 1354-1361.
49. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000; 1: 311-316.
50. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478.
51. Bennett SR et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480.
52. Bonehill A et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172: 6649-6657.
53. Cella M et al. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388: 782-787.
54. Cella M et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999; 189: 821-829.
55. Liao X et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 2004; 9: 757-764.
56. + regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA electroporated dendritic cells. Mol Ther 2005 (in press).